Sponsor Study ID:
Protocol RR3 (CP 03 001), Targeted Intra arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab Paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer (TIGeR PaC)
To compare the Overall Survival, from time of randomization until death, between subjects receiving intra-arterial (IA) delivery of gemcitabine using the RenovoCath® device for 16 weeks vs. continuation of intravenous (IV) gemcitabine and nab-paclitaxel for 16 weeks in those with stable disease following induction therapy with IV gemcitabine and nab-paclitaxel and radiation treatment for unresectable locally advanced pancreatic adenocarcinoma.
(MUSC NetID required for document access)